Methylome Variation Predicts Exemestane Resistance in Advanced ER+ Breast Cancer.

Technology in Cancer Research & Treatment
Xiao-Ran LiuHui-Ping Li

Abstract

More than 30% of estrogen receptor-positive breast cancers are resistant to primary hormone therapy, and about 40% that initially respond to hormone therapy eventually acquire resistance. Although the mechanisms of hormone therapy resistance remain unclear, aberrant DNA methylation has been implicated in oncogenesis and drug resistance. We investigated the relationship between methylome variations in circulating tumor DNA and exemestane resistance, to track hormone therapy efficacy. We prospectively recruited 16 patients who were receiving first-line therapy in our center. All patients received exemestane-based hormone therapy after enrollment. We collected blood samples at baseline, first follow-up (after 2 therapeutic cycles) and at detection of disease progression. Disease that progressed within 6 months under exemestane treatment was considered exemestane resistance but was considered relatively exemestane-sensitive otherwise. We obtained circulating tumor DNA-derived methylomes using the whole-genome bisulfide sequencing method. Methylation calling was done by BISMARK software; differentially methylated regions for exemestane resistance were calculated afterward. Median follow-up for the 16 patients was 19.0 months. We fou...Continue Reading

References

Oct 24, 2006·The Journal of Steroid Biochemistry and Molecular Biology·Shiuan ChenXiwei Wu
Jul 10, 2007·The Journal of Steroid Biochemistry and Molecular Biology·Wei YueRichard J Santen
Mar 14, 2008·The New England Journal of Medicine·Manel Esteller
Jul 2, 2008·Breast Cancer Research and Treatment·Alberto CalabròHolger Sültmann
Aug 20, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nadia HarbeckRalf Lesche
May 29, 2009·CA: a Cancer Journal for Clinicians·Ahmedin JemalMichael J Thun
Apr 21, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M Elizabeth H HammondAntonio C Wolff
Mar 25, 2011·Science Translational Medicine·Fang FangTimothy A Chan
Oct 14, 2011·Chemical Research in Toxicology·Shabana I KhanAsok K Dasmahapatra
Jun 23, 2012·Nature·Shantanu BanerjiMatthew Meyerson
Sep 25, 2012·Nature·UNKNOWN Cancer Genome Atlas Network
Feb 1, 2013·Epigenetics : Official Journal of the DNA Methylation Society·Eric HervouetRégis Delage-Mourroux
Feb 25, 2014·Future Oncology·Saranya ChumsriAngela Brodie
Oct 15, 2014·The Breast : Official Journal of the European Society of Mastology·Elsa DalmauMiguel Ángel Seguí-Palmer
Oct 10, 2015·Cell·Giovanni CirielloCharles M Perou
Jun 9, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Charlotte FribbensNicholas C Turner
Nov 22, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kala VisvanathanAntonio C Wolff
Jul 25, 2017·The American Journal of Pathology·Jason N Rosenbaum, Paul Weisman
Jul 25, 2017·The American Journal of Pathology·Veronica DavalosManel Esteller
May 24, 2018·The Journal of Steroid Biochemistry and Molecular Biology·Cristina AmaralNatércia Teixeira

❮ Previous
Next ❯

Citations

Jul 16, 2021·Frontiers in Oncology·Sara PatriziAdamo Pio d'Adamo

❮ Previous
Next ❯

Methods Mentioned

BETA
blood draws
methyl-seq

Software Mentioned

Bismark
Cutadapt
Perl scripts
hclust
EXEr
R
FastQC

Related Concepts

Related Feeds

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.

Related Papers

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
R Charles CoombesEmma Hall
The Medical Letter on Drugs and Therapeutics
© 2021 Meta ULC. All rights reserved